Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies

Bone Marrow Transplantation

Volumn 17, Issue 6, 1996, Pages 951-956

  Vose, J M ^a   Bierman, P J ^a   Ruby, E ^a   Reed, E C ^a   Bishop, M R ^a   Tarantolo, S ^a   Kessinger, A ^a   Armitage, J O ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

ABMT; Cytokines; Lymphoma

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; IFOSFAMIDE;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOXICITY; FEMALE; HUMAN; HUMAN CELL; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; RASH; THROMBOCYTE; VEIN OCCLUSION;

ADULT; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA; MALE; TRANSPLANTATION, AUTOLOGOUS;

EID: 0030056474     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Horning SJ, Negrin RS, Chao NJ et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2552-2558.
2. Vose JM, Anderson JR, Kessinger A et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846-1851.
3. Petersen FB, Appelbaum FR, Hill R et al. Autologous marrow transplantation for malignant lymphoma: A report of 101 cases from Seattle. J Clin Oncol 1990; 8: 638-647.
4. Freedman AS, Takvorian T, Neuberg D et al. Autologous bone marrow transplantation in poor prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study. J Clin Oncol 1993; 11: 931-936.
5. Freedman AS, Takvorian T, Anderson KC et al. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 1990; 8: 784-791.
6. Appelbaum FR, Herzig GP, Ziegler JL et al. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood 1978; 52: 85-95.
7. Bearman SI, Appelbaum FR, Back A et al. Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 1989; 7: 1288-1294.
8. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
9. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
10. Gerson SL, Talbot GH, Hurwitz S et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984; 100: 345-351.
11. van der Meer JWM, Guiot HFL, van den Broek PJ, van Furth R. Infections in bone marrow transplant recipients. Semin Hematol 1984; 21: 123-140.
12. Nemunaitis J, Singer JW, Buckner CD et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation for lymphoid malignancies. Blood 1988; 72: 834-836.
13. Linch DC, Scarffe H, Proctor S et al. Randomized vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant 1993; 11: 307-311.
14. Nemunaitis J, Rabinowe SN, Singer JW et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. New Engl J Med 1991; 324: 1773-1778.
15. Link H, Boogaerts MA, Carella AM et al. A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 1992; 80: 2188-2195.
16. Gorin NC, Coiffier B, Hayat M et al. Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial. Blood 1992; 80: 1149-1157.
17. Schmitz N, Dreger P, Zander A et al. A randomized, controlled, multicentre study of granulocyte colony stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood 1993; 82: 568a.
18. Stahel RA, Muller E, Pichert G et al. Dose intensification with autologous marrow support in high-risk lymphoma: acceleration of hematopoietic recovery and reduction of days of hospitalisation with granulocyte colony stimulating factor (G-CSF) in a randomized open label trial. Proc ASCO 1992; 11: 1129a.
19. Gulati SC, Bennett CL. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med 1992; 116: 177-182.
20. McNiece I, Andrews R, Stewart M et al. Action of interleukin-3, G-CSF, and GM-CSF on highly enriched human hematopoietic progenitor cells: synergistic interaction of GM-CSF plus G-CSF. Blood 1989; 77: 110-114.
21. Weinthal J, Sender L, Briones G et al. The sequential combination of GM-CSF followed by G-CSF significantly enhances myeloid engraftment compared to GM-CSF alone following bone marrow transplantation. Blood 1993; 82: 1129a.
22. Kaplan GL Meier P. Nonparametric estimation from in complete observations. J Am Stat Assoc 1958; 53: 457-481.
23. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
24. Cebon J, Dempsey P, Fox R et al. Pharmacokinetics of human granulocyte-macrophage colony stimulating factor (hGM-CSF) using a sensitive immunoassay. Blood 1988; 72: 1340-1347.
25. O'Day SJ, Rabinowe SN, Neuberg D et al. A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission. Blood 1994; 83: 2707-2714.
26. Cairo MS, Suen Y, Sender L et al. Circulating granuloctye colony-stimulating factor (G-CSF) levels after allogeneic and autologous bone marrow transplantation: endogenous G-CSF production correlates with myeloid engraftment. Blood 1992; 79: 1869-1873.
27. Bishop MR, Anderson JR, Jackson JD et al. High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. Blood 1994; 83: 610-616.
28. Nademanee A, Sniecinski I, Schmidt GM et al. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 1994; 12: 2176-2186.
29. Haas R, Moos M, Karcher A et al. Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 1685-1692.
30. Chao NH, Schriber JR, Grimes K et al. Granulocyte colony-stimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031-2035.
31. Cannistra SA, Vellenga E, Groshek P et al. Human granuloctye-macrophage colony stimulating factor and interleukin-3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood 1988; 71: 672-676.
32. Thomassen MJ, Ahmad M, Barna BP. Induction of cytokine messenger RNA and secretion in alveolar macrophages and blood monocytes from patients with lung cancer receiving granuloctye-macrophage colony stimulating factor therapy. Cancer Res 1991; 51: 857-862.
33. Thompson JA, Lee DJ, Kidd P et al. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. J Clin Oncol 1989; 7: 629-637.
34. Edmonson JH, Hartmann LC, Long HJ et al. Granulocyte-macrophage colony-stimulating factor: preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin. Cancer 1992 70: 2529-2539.
35. Fay JW, Lazarus H, Herzig R et al. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study. Blood 1994; 84: 2151-2157.
36. Vose JM, Anderson J, Bierman PJ et al. Initial trial of PIXY321 (GM-CSF/IL-3 fusion protein) following high-dose chemotherapy and autologous bone marrow transplantation (ABMT) for lymphoid malignancy. Proc ASCO 1993; 12: 1237a.